Drugs / carrellimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07070479 | Jun 2025 → Jan 2027 expected | nasopharyngeal carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT06472713 | Jul 2024 → Oct 2025 overdue | nasopharyngeal carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carrellimab | “PD-1 blockade (comprising tislelizumab <200 mg/cycle>, carrellimab <200 mg/cycle>, or toripalimab <240 mg/cycle>) once every 3 weeks for two years, or until intolerable...” NCT06472713 ↗1“PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab” NCT07070479 ↗ |
| Action | Inhibit | “PD-1 blockade” NCT06472713 ↗ |
| Modality | Monoclonal antibody | “anti-PD-1 antibody” NCT07070479 ↗ |